Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Primary progressive multiple sclerosis—why we are failing

In The Lancet, Fred Lublin and colleagues1 report negative results of a randomised, double-blind trial (INFORMS) assessing the efficacy of fingolimod, an oral sphingosine 1-phosphate receptor (S1PR) modulator, on disability progression in patients with primary progressive multiple sclerosis. This result is particularly disappointing because no US Food and Drug Administration (FDA)-approved disease-modifying therapies exist for primary progressive multiple sclerosis at present. In contrast to drastic advances during the past 20 years in treatment of relapsing multiple sclerosis, the number of unsuccessful studies in primary progressive multiple sclerosis is substantial.